|
|
Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
|
Oda, Michael N.
,
Forte, Trudy M.
|
05/29/2007 |
7,223,726 |
|
|
|
The present invention provides a synthetic LDL nanoparticle comprising a lipid moiety and a synthetic chimeric peptide so as to be capable of binding the LDL receptor. The synthetic LDL nanoparticle of the present invention is capable of incorporating and targeting therapeutics to cells expressing the LDL receptor for diseases associated with the expression of the LDL receptor such as central nervous system diseases. The invention further provides methods of using such synthetic LDL nanoparticles.
Synthetic LDL as targeted drug delivery vehicle
|
Forte, Trudy M.
,
Nikanjam, Mina
|
08/28/2012 |
8,252,338 |
|
